(Bloomberg) On the (Paxlovid) rebound, Pfizer Inc.’s antiviral medication caused recurrences or prolonged infections more often in real life than in clinical studies. (A rebound of coronavirus occurred in 2.3% of patients on Paxlovid versus 1.7% receiving placebo in a late-stage trial, Pfizer scientists said in September.)
Covid Rebound with Pfizer’s Paxlovid Less Than Expected
- Published Dec 6, 2022